N'-butyl-N'-methylbutane-1,4-diamine | 900717-33-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N'-butyl-N'-methylbutane-1,4-diamine
• 英文别名: N-butyl-N-methylbutane-1,4-diamine
• CAS: 900717-33-1
• 化学式: C₉H₂₂N₂
• 分子量: 158.287
• InChiKey: LBJDILXJJVRNRO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N'-butyl-N'-methylbutane-1,4-diamine 、 4-acetamido-2-methoxybenzoic acid chloride 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以1.2 g的产率得到4-acetamido-N-(4-(N-butyl-N-methylamino)butyl)-2-methoxybenzamide
  参考文献：
  名称：

  Synthesis and Evaluation of Novel Radioiodinated Benzamides for Malignant Melanoma

  摘要：

  The imaging potential of a series of [I-123]benzamides was studied in mice bearing B16F0 melanoma tumors. Compound [I-123]25 exhibited tumor uptake > 8 %ID/g at 1 h, while that of [I-123]14d and [I-123]25 reached a maximum of 9-12 %ID/g at 6 h. Standardized uptake values of [I-123]14d were higher than 100 between 24 and 72 h after injection. In haloperidol treated animals, the tumor uptake of [I-123]14d was not significantly different to controls, while significant reduction of [I-123]25 uptake was observed, supporting that [I-123]14d uptake relates to melanin interaction, whereas part of the mechanism of [I-123]25 uptake is related to its sigma(1)-receptor affinity. Benzamides 14d and 25, which display rapid and high tumor uptake, appear to be promising imaging agents for melanoma detection, while 14d, which displays a long lasting and high melanoma/nontarget ratio, is more suitable for evaluation as a potential radiotherapeutic.

  DOI：

  10.1021/jm0701627
• 作为产物：
  描述：

  4-(N-butyl-N-methylamino)butyronitrile 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 1.0h， 以72%的产率得到N'-butyl-N'-methylbutane-1,4-diamine
  参考文献：
  名称：

  Synthesis and Evaluation of Novel Radioiodinated Benzamides for Malignant Melanoma

  摘要：

  The imaging potential of a series of [I-123]benzamides was studied in mice bearing B16F0 melanoma tumors. Compound [I-123]25 exhibited tumor uptake > 8 %ID/g at 1 h, while that of [I-123]14d and [I-123]25 reached a maximum of 9-12 %ID/g at 6 h. Standardized uptake values of [I-123]14d were higher than 100 between 24 and 72 h after injection. In haloperidol treated animals, the tumor uptake of [I-123]14d was not significantly different to controls, while significant reduction of [I-123]25 uptake was observed, supporting that [I-123]14d uptake relates to melanin interaction, whereas part of the mechanism of [I-123]25 uptake is related to its sigma(1)-receptor affinity. Benzamides 14d and 25, which display rapid and high tumor uptake, appear to be promising imaging agents for melanoma detection, while 14d, which displays a long lasting and high melanoma/nontarget ratio, is more suitable for evaluation as a potential radiotherapeutic.

  DOI：

  10.1021/jm0701627

文献信息

• [EN] NICOTINAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE NICOTINAMIDE
  申请人：AUSTRALIAN NUCLEAR SCIENCE TEC

  公开号：WO2009129573A1

  公开（公告）日：2009-10-29

  A compound comprising a pyridine carboxamide structure, for use in imaging or treating melanoma, is described. An aromatic ring in the structure is substituted with a radiohalogen atom and the substitution on the amide nitrogen atom is such that the compound binds to melanin.

  描述了一种含有吡啶羧酰胺结构的化合物，用于成像或治疗黑色素瘤。结构中的芳香环被取代为一个放射性卤原子，并且酰胺氮原子上的取代使得该化合物与黑色素结合。
• Nicotinamide Derivatives
  申请人：Katsifis Andrew

  公开号：US20110178396A1

  公开（公告）日：2011-07-21

  A compound comprising a pyridine carboxamide structure, for use in imaging or treating melanoma, is described. An aromatic ring in the structure is substituted with a radiohalogen atom and the substitution on the amide nitrogen atom is such that the compound binds to melanin.

  描述了一种含有吡啶羧酰胺结构的化合物，用于成像或治疗黑色素瘤。结构中的芳香环被取代为一个放射性卤原子，酰胺氮原子上的取代使得该化合物与黑色素结合。
• AMINOTHIAZOLE DERIVATIVES, DRUG CONTAINING THE SAME AND INTERMEDIATE IN THE PRODUCTION OF THE COMPOUNDS
  申请人：ZERIA PHARMACEUTICAL CO., LTD.

  公开号：EP0870765A1

  公开（公告）日：1998-10-14

  The present invention relates to an aminothiazole derivative represented by the following formula (I): wherein R1, R2 and R3 each independently represents a hydrogen atom, a hydroxy group, a lower alkyl group, a lower alkoxy group or the like; R4 represents a hydrogen atom or a lower alkyl group; R5 represents a hydrogen atom, a halogen atom or a lower alkyl group; m stands for an integer of 0 to 4, A represents a substituted amino group, a substituted imino group, a heterocyclic group or the like; and B stands for an imino group or an oxygen atom, a medicament containing it and an intermediate for the preparation of said compound. The compound has strong restoration effects on dysmotility in the gastrointestinal tract and at the same time has high safety so that it is useful as an excellent gastroprokinetic.

  本发明涉及下式（I）所代表的氨基噻唑衍生物： 其中 R1、R2 和 R3 各自独立地代表氢原子、羟基、低级烷基、低级烷氧基或类似基团；R4 代表氢原子或低级烷基；R5 代表氢原子、卤素原子或低级烷基；m 代表 0 至 4 的整数；A 代表取代的氨基、取代的亚氨基、杂环基团或类似基团；B 代表亚氨基或氧原子。该化合物对胃肠道运动障碍有很强的修复作用，同时具有很高的安全性，因此可作为一种很好的胃动力药。
• Discovery of [¹⁸F]<i>N</i>-(2-(Diethylamino)ethyl)-6-fluoronicotinamide: A Melanoma Positron Emission Tomography Imaging Radiotracer with High Tumor to Body Contrast Ratio and Rapid Renal Clearance
  作者：Ivan Greguric、Stephen R. Taylor、Delphine Denoyer、Patrice Ballantyne、Paula Berghofer、Peter Roselt、Tien Q. Pham、Filomena Mattner、Thomas Bourdier、Oliver C. Neels、Donna S. Dorow、Christian Loc’h、Rodney J. Hicks、Andrew Katsifis

  DOI：10.1021/jm9008423

  日期：2009.9.10

  The high melanoma uptake and rapid body clearance displayed by our series of [I-123]liodonicotinamides prompted the development of [F-18]N-(2-(diethylamino)ethyl)-6-fluoronicotinamide ([F-18]2), a novel radiotracer for PET melanoma imaging. Significantly, unlike fluorobenzoates, [F-18]fluorine incorporation on the nicotinamide ring is one step, facile, and high yielding. [F-18]2 displayed high tumor uptake, rapid body clearance via predominantly renal excretion, and is currently being evaluated in preclinical studies for progression into clinical trials to assess the responsiveness of therapeutic agents.
• NICOTINAMIDE DERIVATIVES
  申请人：CRC for Biomedical Imaging Development Ltd

  公开号：EP2285778A1

  公开（公告）日：2011-02-23